Testing MB-CART19.1 therapy for severe lupus
Part of Immune system & allergy, Skin clinical trials.
This trial tests a new type of treatment called CAR T-cell therapy (MB-CART19.1) for people with severe lupus that has not responded to other treatments. It aims to see if this therapy can help control lupus and improve organ function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- You must have a diagnosis of SLE with major organ involvement (like kidney, heart, or lungs)
- You must have tried at least two standard lupus treatments and they didn't work well enough
- You must have a certain level of immune cells (CD3+ T cells) and be willing to use contraception for 12 months after treatment
- You must be fully vaccinated against COVID-19 or have had a confirmed infection in the last 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment called CD19/BCMA CAR-T for people with lupus (SLE) that has not improved with standard treatments. The therapy uses your own immune cells, modified to target and calm overactive immune cells, aiming to reduce disease activity.
This trial tests a new CAR-T cell treatment made from donor umbilical cord blood for people with lupus that hasn't improved with at least two standard treatments. The goal is to see if it can help control disease activity.
This trial tests whether a special type of immune cell, called CART19, can help young people with active lupus that hasn't gotten better with standard treatments. If you join, doctors will take some of your blood cells, modify them to attack lupus-causing cells, and then give them back to you.
This early-phase trial tests a special immune cell therapy (CAR-T) for people with lupus nephritis that has not improved with standard treatments. The therapy uses your own modified cells to target and calm the overactive immune system causing kidney damage.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins on immune cells (CD19 and BCMA) to treat lupus that hasn't responded to standard treatments. It may help people with moderate to severe lupus by reducing disease activity without ongoing medication.
This trial tests a new treatment called CAR-T cells, which are specially trained immune cells designed to target and destroy lupus-causing cells. It is for adults with active lupus that has not responded to at least two standard therapies.
Hear when a new SLE - Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.